101 related articles for article (PubMed ID: 7719379)
1. Immunotherapy with low-dose interleukin-2 and anti-transforming growth factor-beta antibody in a murine tumor model.
Mao XW; Kettering JD; Gridley DS
Cancer Biother; 1994; 9(4):317-27. PubMed ID: 7719379
[TBL] [Abstract][Full Text] [Related]
2. Effects of anti-transforming growth factor-beta antibody and interleukin-2 in tumor-bearing mice.
Gridley DS; Sura SS; Uhm JR; Lin CH; Kettering JD
Cancer Biother; 1993; 8(2):159-70. PubMed ID: 7804355
[TBL] [Abstract][Full Text] [Related]
3. Immunotherapy with low-dose interleukin-2 and interferon-gamma in a murine tumor model.
Mao XW; Kettering JD; Gridley DS
J Interferon Cytokine Res; 1995 Dec; 15(12):1017-27. PubMed ID: 8746782
[TBL] [Abstract][Full Text] [Related]
4. Immunotherapy with low-dose interleukin-2 and a polysaccharopeptide derived from Coriolus versicolor.
Mao XW; Archambeau JO; Gridley DS
Cancer Biother Radiopharm; 1996 Dec; 11(6):393-403. PubMed ID: 10851500
[TBL] [Abstract][Full Text] [Related]
5. Modulation of lymphoproliferation and oxidative burst by herpes-transformed tumors.
Gridley DS; Das MR; Lau BH; Kettering JD
Mol Biother; 1991 Jun; 3(2):88-94. PubMed ID: 1654931
[TBL] [Abstract][Full Text] [Related]
6. IL-2 gene and antisense TGF-beta1 strategies counteract HSV-2 transformed tumor progression.
Kettering JD; Mohamedali AM; Green LM; Gridley DS
Technol Cancer Res Treat; 2003 Jun; 2(3):211-21. PubMed ID: 12779352
[TBL] [Abstract][Full Text] [Related]
7. Transforming growth factor-beta (TGF-beta)-mediated immunosuppression in the tumor-bearing state: enhanced production of TGF-beta and a progressive increase in TGF-beta susceptibility of anti-tumor CD4+ T cell function.
Li XF; Takiuchi H; Zou JP; Katagiri T; Yamamoto N; Nagata T; Ono S; Fujiwara H; Hamaoka T
Jpn J Cancer Res; 1993 Mar; 84(3):315-25. PubMed ID: 8098027
[TBL] [Abstract][Full Text] [Related]
8. Augmentation of antitumor effect on syngeneic murine solid tumors by an interleukin 2 slow delivery system, the IL-2 mini-pellet.
Fujiwara T; Sakagami K; Matsuoka J; Shiozaki S; Fujioka K; Takada Y; Uchida S; Onoda T; Orita K
Biotherapy; 1991; 3(3):203-9. PubMed ID: 1854589
[TBL] [Abstract][Full Text] [Related]
9. Antitumor effect of interleukin-1 beta in the double grafted tumor system.
Ebina T; Ishikawa K
Jpn J Cancer Res; 1989 Jun; 80(6):570-6. PubMed ID: 2503477
[TBL] [Abstract][Full Text] [Related]
10. Modulation of transforming growth factor-beta 1 effects by cytokines.
Uhm JR; Kettering JD; Gridley DS
Immunol Invest; 1993 Jul; 22(5):375-88. PubMed ID: 8406627
[TBL] [Abstract][Full Text] [Related]
11. Modulation of B16 melanoma growth and metastasis by anti-transforming growth factor beta antibody and interleukin-2.
Wojtowicz-Praga S; Verma UN; Wakefield L; Esteban JM; Hartmann D; Mazumder A
J Immunother Emphasis Tumor Immunol; 1996 May; 19(3):169-75. PubMed ID: 8811491
[TBL] [Abstract][Full Text] [Related]
12. Suppression of immune responses by herpes virus type 2-transformed murine tumor cells.
Das MR; Gridley DS; Kettering JD
Immunol Lett; 1991 Sep; 30(1):37-45. PubMed ID: 1660030
[TBL] [Abstract][Full Text] [Related]
13. Anti-tumor effects of interleukin-2 and interleukin-1 in mice transplanted with different syngeneic tumors.
Belardelli F; Ciolli V; Testa U; Montesoro E; Bulgarini D; Proietti E; Borghi P; Sestili P; Locardi C; Peschle C
Int J Cancer; 1989 Dec; 44(6):1108-16. PubMed ID: 2606579
[TBL] [Abstract][Full Text] [Related]
14. Use of recombinant human interleukin-2 in conjunction with bone marrow transplantation as a model for control of minimal residual disease in malignant hematological disorders: I. Treatment of murine leukemia in conjunction with allogeneic bone marrow transplantation and IL-2-activated cell-mediated immunotherapy.
Weiss L; Reich S; Slavin S
Cancer Invest; 1992; 10(1):19-26. PubMed ID: 1735011
[TBL] [Abstract][Full Text] [Related]
15. Immunotherapy of minimal residual disease by immunocompetent lymphocytes and their activation by cytokines.
Slavin S; Ackerstein A; Weiss L; Nagler A; Or R; Naparstek E
Cancer Invest; 1992; 10(3):221-7. PubMed ID: 1581831
[TBL] [Abstract][Full Text] [Related]
16. Immunotherapy with anti-CD3 monoclonal antibodies and recombinant interleukin 2: stimulation of molecular programs of cytotoxic killer cells and induction of tumor regression.
Nakajima F; Khanna A; Xu G; Lagman M; Haschemeyer R; Mouradian J; Wang JC; Stenzel KH; Rubin AL; Suthanthiran M
Proc Natl Acad Sci U S A; 1994 Aug; 91(17):7889-93. PubMed ID: 8058730
[TBL] [Abstract][Full Text] [Related]
17. [Mechanisms of enhanced accumulation of transferred LAK cells into tumor sites after chemotherapy].
Kuramitsu Y
Hokkaido Igaku Zasshi; 1995 May; 70(3):507-17. PubMed ID: 7590601
[TBL] [Abstract][Full Text] [Related]
18. Effect of a metalloporphyrin antioxidant (MnTE-2-PyP) on the response of a mouse prostate cancer model to radiation.
Makinde AY; Luo-Owen X; Rizvi A; Crapo JD; Pearlstein RD; Slater JM; Gridley DS
Anticancer Res; 2009 Jan; 29(1):107-18. PubMed ID: 19331139
[TBL] [Abstract][Full Text] [Related]
19. Antitumor effects of a new interleukin-2 slow delivery system on methylcholanthrene-induced fibrosarcoma in mice.
Fujiwara T; Sakagami K; Orita K
J Cancer Res Clin Oncol; 1990; 116(2):141-8. PubMed ID: 2324156
[TBL] [Abstract][Full Text] [Related]
20. A new model of active specific immunotherapy using interleukin-1 and sonicated tumor supernatant in murine tumor system.
Moriguchi Y; Kan N; Okino T; Harada T; Yamasaki S; Ichinose Y; Li L; Sugie T; Imamura M
J Surg Oncol; 1996 Jun; 62(2):78-85. PubMed ID: 8649045
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
